Publication:
Prechemoradiotherapy systemic inflammation response index stratifies stage IIIB/C non-small-cell lung cancer patients into three prognostic groups: a propensity score-matching analysis

Thumbnail Image

Organizational Units

Program

KU Authors

Co-Authors

Topkan, Erkan
Küçük, Ahmet
Haksöyler, Veysel
Özdemir, Yurday
Mertsoylu, Hüseyin
Besen, Ali Ayberk
Özyılkan, Özgür
Pehlivan, Berrin

Advisor

Publication Date

Language

English

Journal Title

Journal ISSN

Volume Title

Abstract

Purpose: we explored the prognostic influence of the systemic inflammation response index (SIRI) on the survival outcomes of stage IIIB/C non-small-cell lung cancer (NSCLC) patients who underwent concurrent chemoradiotherapy. Methods: present propensity score-matching (PSM) analysis comprised 876 stage IIIB/C NSCLC patients who received 1-3 cycles of platinum-based doublets concurrent with thoracic radiotherapy from 2007 to 2017. The primary and secondary objectives were the relationships between the SIRI values and overall (OS) and progression-free survival, respectively. Propensity scores were calculated for SIRI groups to adjust for confounders and to facilitate well-balanced comparability between the SIRI groups by creating 1 : 1 matched study groups. Results: the receiver operating characteristic curve analysis identified an optimal SIRI cutoff at 1.9 for OS (AUC: 78.8%; sensitivity: 73.7%; specificity: 70.7%) and PFS (AUC: 80.5%; sensitivity: 75.8%; specificity: 72.9%) and we grouped the patients into two PSM cohorts: SIRI < 1.9 (N = 304) and SIRI >= 1.9 (N = 304), respectively. The SIRI >= 1.9 cohort had significantly worse median OS (P<0.001) and PFS (P<0.001) than their SIRI < 1.9 companions. The further combination of SIRI with disease stage exhibited that the SIRI-1 (IIIB and SIRI < 1.9) and SIRI-3 (IIIC and SIRI >= 1.9) cohorts had the best and worst outcomes, respectively, with SIRI-2 cohort (IIIB and SIRI >= 1.9 or IIIC and SIRI < 1.9) being remained in between (P<0.001 for OS and PFS, separately). In multivariate analysis, the two- and three-laddered stratifications per the 1.9 cutoffs and SIRI groups retained their independent significance, individually. Conclusions: the SIRI >= 1.9 independently prognosticated significantly worse OS and PFS results and plated the stage IIIB/C patients into three fundamentally distinct prognostic groups.

Description

Source:

Journal of Oncology

Publisher:

Hindawi

Keywords:

Subject

Medicine, Oncology

Citation

Endorsement

Review

Supplemented By

Referenced By

Copy Rights Note

0

Views

1

Downloads

View PlumX Details